Epclusa Coadministration With Rivaroxaban

Gilead Sciences, Inc.
is providing this document to you,

a US Healthcare Professional, in response to your
unsolicited request for medical information.
Epclusa® (sofosbuvir/velpatasvir)
Coadministration with Rivaroxaban
This document is in response to your request for information on Epclusa®
(sofosbuvir/velpatasvir) and coadministration with rivaroxaban.
Some data may be outside of the US FDA-approved Prescribing Information. In providing
this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance
or to the use of any Gilead product(s). For information about the approved conditions of use
of any Gilead drug product, please consult the FDA-approved Prescribing Information.
The full indication, important safety information, and boxed warnings are available at :
www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi
PK DDI Evaluation 1,2

Drug interaction studies have not been conducted between the single-tablet regimen
SOF/VEL and rivaroxaban. Based on the PK profile of each active ingredient within
SOF/VEL and rivaroxaban, a PK interaction would be predicted. Coadministration may
increase rivaroxaban concentrations due to inhibition of P-gp and BCRP by VEL. The
clinical significance of this interaction is unknown. For more information about rivaroxaban,
please refer to its product labeling.
SOF/VEL PK1
DDI Mechanism SOF VEL
P-gp/BCRP Substrate Substrate/Inhibitor
OATP1B1 NA Inhibitor
Drug Transporters
CYP1A2 NA NA
CYP2B6 NA Substrate
CYP2C8 NA Substrate
Drug Metabolizing Enzymes
CYP2C9/19 NA NA
CYP2D6 NA NA
CYP3A4 NA Substrate
Relevant SOF/VEL Label Information 1

There is no information in the SOF/VEL product labeling about the coadministration of
SOF/VEL and rivaroxaban.
Clearance of HCV infection with direct-acting antivirals may lead to changes in hepatic
function, which may impact safe and effective use of concomitant medications. Frequent
monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments
of certain concomitant medications may be necessary. For more information, please refer to
Intended for U.S. Healthcare Professionals only

Last Updated: 27 Mar 2023
Gilead Sciences, Inc. is providing this document to you, a US Healthcare Professional, in response to your unsolicited
request for medical information.
Section 7.3 of the Epclusa US Prescribing Information (Established and Potentially

Significant Drug Interactions).
Clinical Data on Coadministration of SOF/VEL and

Rivaroxaban
Retrospective International Multicenter Cohort Study 3
A retrospective, multicenter, international cohort study evaluated the safety of DOACs with
concomitant use of DAAs in adult HCV patients with or without cirrhosis. The primary
endpoint was the incidence of clinically relevant bleeding, including major bleeding and
clinically relevant nonmajor bleeding.
Of the 204 patients, 29.2% (49/168) without cirrhosis and 47.2% (17/36) with cirrhosis
received concomitant SOF/VEL. In the overall population, the DOAC rivaroxaban was
prescribed in 59.2% (100/168) of adults without cirrhosis and 44.4% (16/36) of adults with
cirrhosis. Three patients (1.5%) experienced major bleeding, including 1 patient who was
receiving SOF/VEL with concomitant apixaban, and none experienced clinically relevant
nonmajor bleeding. None of the patients who had major bleeding were receiving
rivaroxaban. Six patients (3%) discontinued use of DOACs; none of these discontinuations
were linked to a specific DAA.
References
1. Enclosed. Gilead Sciences Inc, EPCLUSA® (sofosbuvir and velpatasvir) tablets, for oral
use. US Prescribing Information. Foster City, CA.
2. Janssen Pharmaceuticals Inc. XARELTO (rivaroxaban) tablets, for oral use. US
Prescribing Information (USPI). Titusville, NJ.
3. McDaniel K, Utz AE, Akbashev M, et al. Safe co-administration of direct-acting antivirals
and direct oral anticoagulants among patients with hepatitis C virus infection: An
international multicenter retrospective cohort study. J Viral Hepat. 2022;29(12):1073-
1078.
Abbreviations
BCRP=breast cancer DOAC= direct oral transporting polypeptide
resistance protein anticoagulants P-gp=p-glycoprotein
CYP=cytochrome INR=international PK=pharmacokinetic
DAA=direct-acting antiviral normalized ratio SOF=sofosbuvir
DDI=drug-drug interaction NA=not applicable VEL=velpatasvir
OATP=organic anion
Page 2 of 3
Product Label
For the full indication, important safety information, and Boxed Warning(s), please refer to
the Epclusa US Prescribing Information available at:
www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.
Follow-Up
For any additional questions, please contact Gilead Medical Information at:
☎1‐866‐MEDI‐GSI (1‐866‐633‐4474) or  www.askgileadmedical.com
Adverse Event Reporting

Please report all adverse events to:
Gilead Pharmacovigilance and Epidemiology ☎ 1-800-445-3235, option 3 or
 https://www.gilead.com/utility/contact/report-an-adverse-event
FDA MedWatch Program by ☎ 1-800-FDA-1088 or MedWatch, FDA, 5600 Fishers Ln,
Rockville, MD 20852 or  www.accessdata.fda.gov/scripts/medwatch
Data Privacy
The Medical Information service at Gilead Sciences may collect, store, and use your
personal information to provide a response to your medical request. We may share your
information with other Gilead Sciences colleagues to ensure that your request is addressed
appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite
product, we will need to use the information you have given us in order to meet our
regulatory requirements in relation to the safety of our medicines.
It may be necessary for us to share your information with Gilead’s affiliates, busine ss
partners, service providers and regulatory authorities located in countries besides your own.
Gilead Sciences has implemented measures to protect the personal information you
provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for
more information about how Gilead handles your personal information and your rights. If
you have any further questions about the use of your personal information, please contact
[email protected] .
EPCLUSA, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences,
Inc., or its related companies.
© 2019 Gilead Sciences, Inc.
Page 3 of 3

Epclusa Coadministration With Rivaroxaban

Uploaded by

Copyright:

Available Formats

Epclusa Coadministration With Rivaroxaban

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Epclusa Coadministration With Rivaroxaban

Uploaded by

Copyright:

Available Formats

Gilead Sciences, Inc.

is providing this document to you,

PK DDI Evaluation 1,2

Relevant SOF/VEL Label Information 1

Intended for U.S. Healthcare Professionals only

Section 7.3 of the Epclusa US Prescribing Information (Established and Potentially

Clinical Data on Coadministration of SOF/VEL and

Adverse Event Reporting

You might also like